first glp 1 approval Ozempic is GLP-1 drug FDA-approved for kidney disease Novo Nordisk's CagriSema: First Fixed-Dose
Description
It works by simultaneously activating three receptors glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors producing significant reductions in body weight and improvements in metabolic markers
and in the heart and kidneys

doi: 10.1161/CIRCULATIONAHA.116.021887
That is the answer for every FDA-approved oral GLP-1 tablet currently on the market
